| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $86,402,031 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | U01AI187020 | Thioredoxin derivatives for radiation mitigation | 003 | 3 | NIH | 8/13/2026 | $489,684 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R25CA274172 | Native American Youths Enjoy Science - YES Oklahoma | 000 | 5 | NIH | 8/14/2026 | $338,575 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK134316 | Novel Roles of Cullin-RING E3 Ligases in Liver Pathophysiology | 000 | 4 | NIH | 1/30/2026 | $392,869 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R25CA291599 | Cancer Undergraduate Research Experience (CURE) in Oklahoma | 001 | 2 | NIH | 7/24/2026 | $211,635 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01DA062632 | Addiction potential, flavoring content, and substitutability of concept flavored cigarillos | 001 | 2 | NIH | 6/3/2026 | $721,157 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F99CA305566 | Evaluating the role of the tumor macroenvironment in cancer cachexia | 000 | 2 | NIH | 7/20/2026 | $43,234 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | U54GM104938 | Oklahoma Shared Clinical and Translational Resources | 001 | 14 | NIH | 7/7/2026 | $3,999,999 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R35GM160442 | Dynamics of Fungal Stress Responses in the Host Environment | 000 | 2 | NIH | 6/23/2026 | $393,250 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01CA260449 | Exploiting gold nanoparticle as a probe to identify therapeutic targets | 001 | 5 | NIH | 4/16/2026 | $35,496 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA260449 | Exploiting gold nanoparticle as a probe to identify therapeutic targets | 000 | 5 | NIH | 12/4/2025 | $319,463 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31DK146691 | Role of interferon gamma in injury accelerated cystic kidney disease | 002 | 1 | NIH | 4/10/2026 | $576 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31DK146691 | Role of interferon gamma in injury accelerated cystic kidney disease | 001 | 1 | NIH | 12/19/2025 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DK146691 | Role of interferon gamma in injury accelerated cystic kidney disease | 000 | 1 | NIH | 12/19/2025 | $41,422 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | UG1CA233193 | A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials | 003 | 7 | NIH | 6/8/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | UG1CA233193 | A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials | 002 | 7 | NIH | 5/27/2026 | $1,290,000 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31DE034904 | Early-Stage Autoimmunity in Sjögren's Disease and Systemic Lupus Erythematosus | 000 | 3 | NIH | 8/20/2026 | $38,131 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | U01CA294811 | Implementing Sustainable mobile health Technology to Optimize smoking cessation Program for people with HIV (I-STOP) | 002 | 3 | NIH | 7/31/2026 | $111,521 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | U01CA294811 | Implementing Sustainable mobile health Technology to Optimize smoking cessation Program for people with HIV (I-STOP) | 001 | 3 | NIH | 7/22/2026 | $520,889 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 003 | 3 | NIH | 8/12/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 002 | 3 | NIH | 6/29/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 001 | 3 | NIH | 4/17/2026 | $81,384 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 000 | 3 | NIH | 1/30/2026 | $732,478 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F30NS143384 | Determining the Role of Mitochondrial Hydrogen Peroxide in the Regulation of Neuronal Mitochondrial Networks | 001 | 1 | NIH | 2/17/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R03CA301367 | Evaluating inherited genetic variation and outcome among children andadolescents treated for acute myeloid leukemia | 001 | 1 | NIH | 5/28/2026 | $21,500 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R03CA301367 | Evaluating inherited genetic variation and outcome among children andadolescents treated for acute myeloid leukemia | 000 | 1 | NIH | 4/21/2026 | $318,411 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01MD021599 | Tailored Mobile Health Technology to Address Native American Chronic Pain | 000 | 1 | NIH | 9/1/2026 | $715,543 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01CA299966 | A Randomized Controlled Trial On Improving Prostate Cancer Screening Among Black Men in Oklahoma Using A Community-Based mHealth Approach (Prostate Cancer Genius App) | 000 | 1 | NIH | 5/19/2026 | $592,731 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01CA293516 | Phase I/II clinical trial of in-house BCMA CAR T-cell therapy and opaganib in ultrahigh risk multiple myeloma | 000 | 1 | NIH | 8/18/2026 | $628,602 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01HL182864 | Hypothalamic MC4R signaling pathways in sympathetic regulation of blood pressure | 000 | 1 | NIH | 8/7/2026 | $638,245 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R00GM157498 | Role of Protein N-Myristoylation in Driving DNA Damage Response | 000 | 3 | NIH | 8/5/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | K08HL181276 | Role of MPST and Mitochondrial Bioenergetics in Hyperoxia-induced Neonatal Airway Disease | 000 | 1 | NIH | 8/27/2026 | $152,388 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31AI197827 | Investigating the role of T cell-derived acetylcholine during Influenza A Virus infection | 002 | 1 | NIH | 6/3/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31AI197827 | Investigating the role of T cell-derived acetylcholine during Influenza A Virus infection | 001 | 1 | NIH | 4/27/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31AI197827 | Investigating the role of T cell-derived acetylcholine during Influenza A Virus infection | 000 | 1 | NIH | 4/27/2026 | $47,914 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01AG088321 | Adipose-brain crosstalk in age-related vascular cognitive impairment: Mechanisms and mediators | 000 | 1 | NIH | 8/26/2026 | $43,626 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01AG088321 | Adipose-brain crosstalk in age-related vascular cognitive impairment: Mechanisms and mediators | 000 | 1 | NIH | 8/26/2026 | $350,000 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01DK147452 | Defining the role of Polycystin 1 as a G protein coupled receptor in kidney cystogenesis | 000 | 1 | NIH | 4/21/2026 | $620,185 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31MH143445 | The Impact of DNA Methylation on Microglial Innate Immune Memory Following Prenatal Immune Activation | 001 | 1 | NIH | 8/6/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31MH143445 | The Impact of DNA Methylation on Microglial Innate Immune Memory Following Prenatal Immune Activation | 000 | 1 | NIH | 8/6/2026 | $47,914 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 Research Pkwy Ste 560 | Oklahoma City | OK | 73104-3650 | OKLAHOMA | USA | T3555310 | Primary Care Training and Enhancement -- Residency Training in Street Medicine | 00 | 2 | HRSA | 5/14/2026 | $500,000 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R21AI193667 | Determining the role of the cytokine interleukin-22 (IL-22) in SARS-CoV-2 infection | 000 | 1 | NIH | 8/10/2026 | $178,750 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F30AI203126 | Identification and functional characterization of ultra-rare variants in childhood lupus | 000 | 1 | NIH | 8/19/2026 | $38,889 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R00AG086524 | Investigating TFEB as a critical node to improve proteostatic maintenance and skeletal muscle function with age | 000 | 3 | NIH | 8/24/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31DK146724 | Skeletal muscle MIRO1 Mediates Insulin Resistance and Muscular Complications in Type 2 Diabetes | 001 | 1 | NIH | 8/10/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | F31DK146724 | Skeletal muscle MIRO1 Mediates Insulin Resistance and Muscular Complications in Type 2 Diabetes | 000 | 1 | NIH | 8/10/2026 | $50,114 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | K01DK144648 | The function of injury-specific macrophages in acute kidney injury | 000 | 2 | NIH | 7/3/2026 | $159,386 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R21AG103782 | Alpha-Ketoglutarate: A Novel Therapeutic Strategy to Improve Neurogliovascular Coupling and Cognitive Aging in Older Adults | 000 | 1 | NIH | 8/31/2026 | $214,500 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R03DE036378 | Mechanistic insights into cisplatin resistance during secondhand smoke exposure | 000 | 1 | NIH | 9/17/2026 | $286,000 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY STE 560 | OKLAHOMA CITY | OK | 73104-3650 | OKLAHOMA | USA | R01CA303462 | Targeting Progesterone Resistance for Endometrial Cancer Prevention | 000 | 1 | NIH | 9/10/2026 | $437,142 |
|
